- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03894579
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
BC
-
Tijuana, BC, Mexico, 22010
- Hospital Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be considered eligible for participation in the study if all the following inclusion criteria are satisfied:
- Informed consent obtained before any "trial-related activities" (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
- Diagnosis of plaque psoriasis for at least 6 months with at least one psoriatic plaque measuring between 2 cm and 5 cm at the time of screening
If female, subject is either not of childbearing potential (postmenopausal for at least 1 year or surgically sterile) or is of childbearing potential and is using approved method of birth control throughout study and for 1 month after last dose of study drug. Approved methods of birth control include the following:
- Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (IUD)
- Hormonal contraceptives for 90 days prior to study drug administration
- A vasectomized partner
Subject must be able and willing to provide written informed consent and comply with requirements of this study protocol
Following Eligibility & Consent:
- Subject must be able to donate 130 ml to 490 ml of blood for NKMax America to obtain an adequate number of autologous NK cells necessary to establish the final investigational product
- Successful establishment of the final NK product, or "study therapy", established by NKMax America
Exclusion Criteria:
Subjects who fulfill any of the following criteria will not be recruited into the study:
- Subjects with severe medical condition(s) that in the view of the investigator prohibits participation in the study
- Subject has Netherton's syndrome or other genodermatoses that results in a defective epidermal barrier
- Subjects who have applied topical medication (prescription or over-the-counter) for the treatment of psoriasis to their body within 7 days of the baseline visit
- Subjects who have taken cyclosporine, methotrexate, immuran, oral retinoids, chemotherapeutic agents, anti-inflammatory biologics (e.g., alefacept, etanercept, etc.), or oral calcineurin inhibitors within 28 days of the whole blood donation visit for the establishment of the investigational product
- Subjects who are unable to hold their current psoriasis medications for the period of time indicated (at least 7 days for topical medications, at least 28 days for oral or injectable medications) without significant worsening of their psoriasis
- Immunocompromised subjects (e.g., lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome) or subjects with a history of malignant disease (excluding non-melanoma skin cancer) as determined by the participant's medical history
- Subjects receiving phototherapy (e.g., ultraviolet light B [UVB], psoralen plus ultraviolet light A [PUVA]) within 28 days of the baseline visit.
- Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol.
- Subjects with significant concurrent medical condition(s) at screening that in the view of the investigator prohibits that in the view of the investigator prohibits participation in the study (e.g., severe concurrent allergic disease, condition associated with malignancy, and condition associated with immunosuppression)
- Subjects with an active bacterial, viral or fungal skin infection (excluding nail fungus)
- Ongoing participation in an investigational drug trial
- Presence of psoriasis with exfoliative erythroderma or presence of guttate psoriasis, primary palmoplantar psoriasis, or pustular psoriasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SNK01
SNK01 infused weekly for 4 consecutive weeks
|
SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary endpoint for safety is the dose-limiting toxicity (DLT)
Time Frame: From enrollment to end of treatment at 8 Weeks
|
DLT is a TEAE of grade ≥3 considered related to SNK01
|
From enrollment to end of treatment at 8 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary Efficacy by Physician Global Assessment (PGA)
Time Frame: From enrollment to end of treatment at 8 Weeks
|
The Physician Global Assessment (PGA) is a 6-point scoring system used to assess disease severity at a given time point.
The PGA is a six-point score that summarizes the overall quality (erythema, scaling and thickness) and extent of Psoriasis plaques where (0) is clear, (1) minimal, (2) mild, (3) moderate, (4) severe, and (5) being very severe psoriasis.
Change in score from baseline through Week 8 will be assessed.
|
From enrollment to end of treatment at 8 Weeks
|
Preliminary Efficacy by Psoriasis Area and Severity Index (PASI)
Time Frame: From enrollment to end of treatment at 8 Weeks
|
Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis.
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).
Change in score from baseline through Week 8 will be assessed.
|
From enrollment to end of treatment at 8 Weeks
|
Secondary Safety Measures: Other Non-DLT Adverse Events
Time Frame: From enrollment to end of treatment at 8 Weeks
|
Frequency and type of Non-DLT adverse events (graded according to National Cancer Institute's Common Toxicity Criteria for Adverse Events [NCI-CTCAE v 5.0]),
|
From enrollment to end of treatment at 8 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniela Gutiérrez, MD, Hospital Angeles Tijuana
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNK01-MX03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Biocon Biologics Inc.MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. LtdCompletedHulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis | Severe Chronic Plaque PsoriasisBulgaria, Czechia, Estonia, Poland
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
Clinical Trials on Study Product: SNK01
-
NKGen Biotech, Inc.TerminatedAlzheimer Disease | Neuro-Degenerative DiseaseMexico
-
Shenzhen Precision Health Food Technology Co. Ltd...Active, not recruiting
-
Radicle ScienceActive, not recruitingRadicle Recharge: A Study of Health and Wellness Products on Energy Levels and Other Health OutcomesFatigue | EnergyUnited States
-
NKGen Biotech, Inc.Affimed GmbHTerminatedCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of Head and Neck | Advanced Solid Tumor | Metastatic Tumor | Refractory TumorUnited States
-
Radicle ScienceActive, not recruitingSleep Disorder | Sleep | Sleep DisturbanceUnited States
-
Radicle ScienceRecruitingPain | Neuropathic Pain | Nociceptive PainUnited States
-
Radicle ScienceActive, not recruitingCognitive FunctionUnited States
-
Abbott NutritionCompleted
-
Medicus Research, LLCCompleted
-
Radicle ScienceActive, not recruitingStress | AnxietyUnited States